In premarket trading on July 31, 2026, Eastern Time, global pharmaceutical giant Pfizer (PFE) announced a major breakthrough in a Phase III clinical trial of its oral GLP-1 receptor agonist for obesity. The data showed that the drug helped patients achieve an average weight loss of 15.2% over the 68-week trial, significantly better than the placebo group, with a favorable safety profile. Following the announcement, Pfizer shares surged more than 15% in premarket trading, lifting the entire US pharmaceutical sector.
Market Reaction: All Three Index Futures Rise
The blockbuster news quickly spread to the broader market. As of writing, Dow Jones Industrial Average futures rose 0.6%, S&P 500 futures gained 0.4%, and the tech-heavy Nasdaq 100 futures edged up 0.2%. The pharmaceutical sector was the standout in early trading, with the SPDR Health Care Select Sector ETF (XLV) rising nearly 2% premarket.
Notably, other players in the weight-loss drug space—Eli Lilly (LLY) and Novo Nordisk (NVO)—also moved in tandem, gaining 1.8% and 1.2% respectively. The market believes Pfizer's success will further expand the growth potential of the entire weight-loss drug market, rather than being a zero-sum game.
Pfizer's Ambition and Industry Background
Pfizer's journey in the GLP-1 space has been bumpy. Previously, the company discontinued development of two oral weight-loss drugs due to liver injury concerns, raising doubts about whether Pfizer could catch up with Eli Lilly and Novo Nordisk. Now, PF-069—a next-generation oral small-molecule drug developed in-house—avoids earlier safety pitfalls and shows efficacy comparable to injectable drugs.
According to the latest report from an international consultancy, the global obesity drug market reached approximately $50 billion in 2025 and is expected to exceed $150 billion by 2030. Currently, Novo Nordisk's semaglutide and Eli Lilly's tirzepatide dominate, but the convenience of oral drugs could help Pfizer carve out a place in this vast market.
Several Wall Street analysts said in recent research notes that if the drug ultimately receives FDA approval, peak sales could reach $8 billion to $10 billion, making it Pfizer's next mega-blockbuster after its COVID-19 vaccine. Jefferies analysts noted: “Pfizer's clinical data show that oral drugs can match injectables in efficacy, meaning competition will shift from ‘route of administration’ to ‘overall benefits.’”
Industry Analysis: Weight-Loss Drug Market Enters a 'Three-Way Battle' Era
Over the past two years, weight-loss drugs have nearly dominated pharma stock trends. Novo Nordisk and Eli Lilly have reaped huge profits from GLP-1 drugs, while Pfizer's breakthrough will directly challenge the duopoly.
However, some experts warn of risks. Given Pfizer's previous failures with oral weight-loss drugs, the FDA will conduct a stricter safety review. In addition, capacity constraints are a major challenge for Pfizer. Currently, the weight-loss drug market remains in short supply; whoever can achieve large-scale production first will gain the advantage.
From an industry chain perspective, the weight-loss drug boom has also driven related supply chain companies, such as peptide APIs and oral formulation excipients. US-listed contract development and manufacturing organizations (CDMOs) like Catalent (CTLT) have also attracted capital inflows.
Investor Takeaways: Focus on Sector Rotation and ETF Allocation
For investors in Asia and Southeast Asia, changes in the US pharma sector are also relevant. Weight-loss drugs are not only a medical issue, but also a global consumer healthcare trend. Investors can directly trade individual stocks through US brokerage accounts, or choose related ETFs for basket allocation.
- Individual stock picks: Besides Pfizer, Eli Lilly, Novo Nordisk, AbbVie and others have weight-loss drugs in development or on the market.
- ETF allocation: Healthcare ETFs such as XLV and IBB can diversify stock risk and benefit from the pharma innovation wave over the long term.
- Risk warning: Clinical data and regulatory approvals remain uncertain, and high volatility requires investors to manage position sizes.
In addition, overall US market sentiment was bolstered by the positive news. After the Fed kept interest rates unchanged in July, confidence in a soft economic landing grew, and defensive sectors like pharmaceuticals regained capital favor. Some traders said weight-loss drug themes could become one of the sustainable highlights in US stocks in the second half of the year.
What to Watch Next
Pfizer plans to disclose more detailed Phase III data at its upcoming Investor Day and submit a new drug application to the FDA. Meanwhile, research on the drug for diabetes indications is also progressing. If all goes well, Pfizer could receive its first approval by the end of 2027.
Today, US markets will see more economic data, including the June PCE inflation indicator. While enjoying the pharma stock rally, investors should also be wary of rate concerns triggered by stronger-than-expected inflation data.
